Videos

Rucaparib in Recurrent Ovarian Cancer: ARIEL3 Trial

April 27th 2018

Optimizing Therapy in Recurrent Ovarian Cancer

April 27th 2018

Frontline Bevacizumab Strategies in Ovarian Cancer

April 27th 2018

Approaching a Case of Advanced Serous Ovarian Cancer

April 27th 2018

A Case of Advanced Serous Ovarian Cancer

April 27th 2018

A Case of Advanced Serous Ovarian Cancer

Recurrent Ovarian Cancer: Third-Line Therapy and Beyond

April 27th 2018

Defining Rucaparib's Value in Recurrent Ovarian Cancer

April 27th 2018

Recurrent Ovarian Cancer: Selecting Second-Line Therapy

April 27th 2018

Approaching Frontline Therapy Options for Ovarian Cancer

April 27th 2018

A Case of Platinum-Sensitive Epithelial Ovarian Cancer

April 27th 2018

A Case of Platinum-Sensitive Epithelial Ovarian Cancer

April 27th 2018

A Case of Platinum-Sensitive Epithelial Ovarian Cancer

CLL: Combination Therapies and Future Outlook

April 27th 2018

Therapeutic Approach for CLL Progression

April 27th 2018

CLL: Rationale for Ibrutinib and Chemotherapy

April 27th 2018

Treatment Options for CLL

April 27th 2018

Risk Stratifying a Case of CLL

April 27th 2018

Treating Chronic Lymphocytic Leukemia in Elderly Patients

April 27th 2018

Treating Chronic Lymphocytic Leukemia in Elderly Patients

Case 4: Maintenance Strategies in CLL

April 26th 2018

Case 4: iFCR in Untreated CLL

April 26th 2018

Case 4: iFCG in Untreated CLL

April 26th 2018

Case 4: A Young, Fit Patient With MRD-Positive CLL After Immunochemotherapy

April 26th 2018

Case 3: Therapeutic Approaches for Richter Transformation

April 26th 2018

Case 3: Progression on Ibrutinib Followed by Richter Transformation

April 26th 2018

Case 3: Response to Frontline Therapy and Toxicity Management

April 26th 2018

Case 3: Elderly Patient With CLL, Mutated TP53 and NOTCH, Unmutated IgHV

April 26th 2018

Case 2: Treatment Options: Venetoclax +/- Rituximab

April 26th 2018

Case 2: 17p-Deleted CLL Progressing on Ibrutinib Therapy

April 26th 2018

Case 1: Treatment Decision: Ibrutinib Monotherapy

April 26th 2018

Case 1: Targeted Therapy: Ibrutinib for Newly Diagnosed CLL

April 26th 2018

Case 1: Prognostic Features and Chemoimmunotherapy Treatment Options

April 26th 2018

Videos

Rucaparib in Recurrent Ovarian Cancer: ARIEL3 Trial

Optimizing Therapy in Recurrent Ovarian Cancer

Frontline Bevacizumab Strategies in Ovarian Cancer

Approaching a Case of Advanced Serous Ovarian Cancer

A Case of Advanced Serous Ovarian Cancer

Recurrent Ovarian Cancer: Third-Line Therapy and Beyond

Defining Rucaparib's Value in Recurrent Ovarian Cancer

Recurrent Ovarian Cancer: Selecting Second-Line Therapy

Approaching Frontline Therapy Options for Ovarian Cancer

A Case of Platinum-Sensitive Epithelial Ovarian Cancer

A Case of Platinum-Sensitive Epithelial Ovarian Cancer

CLL: Combination Therapies and Future Outlook

Therapeutic Approach for CLL Progression

CLL: Rationale for Ibrutinib and Chemotherapy

Treatment Options for CLL

Risk Stratifying a Case of CLL

Treating Chronic Lymphocytic Leukemia in Elderly Patients

Case 4: Maintenance Strategies in CLL

Case 4: iFCR in Untreated CLL

Case 4: iFCG in Untreated CLL

Case 4: A Young, Fit Patient With MRD-Positive CLL After Immunochemotherapy

Case 3: Therapeutic Approaches for Richter Transformation

Case 3: Progression on Ibrutinib Followed by Richter Transformation

Case 3: Response to Frontline Therapy and Toxicity Management

Case 3: Elderly Patient With CLL, Mutated TP53 and NOTCH, Unmutated IgHV

Case 2: Treatment Options: Venetoclax +/- Rituximab

Case 2: 17p-Deleted CLL Progressing on Ibrutinib Therapy

Case 1: Treatment Decision: Ibrutinib Monotherapy

Case 1: Targeted Therapy: Ibrutinib for Newly Diagnosed CLL

Case 1: Prognostic Features and Chemoimmunotherapy Treatment Options

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Phase 3 Data Highlight Orca-T’s Clinical Benefits in Heme Malignancies

Targeting HER2-Low Breast Cancer: the ARX788 Phase 2 Clinical Trial

ctDNA Refines Risk in Neoadjuvant-Resistant Breast Cancer

High Survival Seen with Nogapendekin Alfa Inbakicept in Papillary NMIBC

PLT012 Receives IND Clearance from FDA for Solid Tumors